糖尿病の治療薬として利用されていたGLP-1 (glucagon-like peptide-1) 受容体アゴニストが、肥満症に対しても有効であることが明らかになり、近年、注目を集めています。現在販売されている主なGLP-1製剤として、Eli Lilly社のDulaglutide（商品名Trulicity）、Tirzepatide ...

The Big Pharma already has efinopegdutide, a dual GLP-1/glucagon receptor co-agonist that Merck touted last year as beating Novo Nordisk's blockbuster GLP-1 drug Ozempic in a phase 2 trial in the ...

Next, the authors set out to specifically target these LepR Glp1r neurons by designing a dual GLP1-R/LepR agonist using previously validated analogues of leptin and GLP-1. The GLP-1RA features a ...

That is perhaps why there has been so much buzz surrounding the class of drug known as a GLP-1 agonist. Medications with the brand names Ozempic, Wegovy, Zepbound, and Mounjaro have garnered ...

Novo Nordisk has filed another Citizen's Petition with the FDA seeking to block compounding pharmacies in the US from making versions of one of its GLP-1 agonist drugs. The latest attempt focuses ...

GLP-1 RAs might lower kidney failure risk in patients with lupus nephritis by reducing pro-inflammatory mediators. Glucagon-like peptide-1 receptor agonist (GLP-1RA) treatment in patients with lupus ...

The greatest weight loss was reported in an RCT of retatrutide (12 mg once weekly), a triple agonist targeting GLP-1, GIP, and glucagon receptors that is not yet FDA-approved or commercially ...

A recent study published in JAMA Network Open has revealed an unexpected connection between GLP-1 receptor agonist medications, commonly used for weight management, and a reduction in alcohol ...

an investigational preclinical oral small molecule GLP-1 receptor agonist. “We continue to leverage science-driven business development to augment and complement our robust pipeline,” said Dr.